Sustained delivery of 17β-estradiol by human amniotic extracellular matrix (HAECM) scaffold integrated with PLGA microspheres for endometrium regeneration

Yue Chen, Weidong Fei, Yunchun Zhao, Fengmei Wang, Xiaoling Zheng, Xiaofei Luan and Caihong Zheng

Department of Pharmacy, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China

ABSTRACT
The endometrial injury usually results in intrauterine adhesions (IUAs). However, there is no effective treatment to promote the regeneration of the endometrium currently. The decellularized amnion membrane (AM) is a promising material in human tissue repair and regeneration due to its biocompatibility, biodegradability, as well as the preservation of abundant bioactive components. Here, an innovative drug-delivering system based on human amniotic extracellular matrix (HAECM) scaffolds were developed to facilitate endometrium regeneration. The 17β-estradiol (E2) loaded PLGA microspheres (E2-MS) were well dispersed in the scaffolds without altering their high porosity. E2 released from E2-MS-HAECM scaffolds in vitro showed a decreased initial burst release followed with a sustained release for 21 days, which coincided with the female menstrual cycle. Results of cell proliferation suggested E2-MS-HAECM scaffolds had good biocompatibility and provided more biologic guidance of endometrial cell proliferation except for mechanical supports. Additionally, the mRNA expression of growth factors in endometrial cells indicated that HAECM scaffolds could upregulate the expression of EGF and IGF-1 to achieve endometrium regeneration. Therefore, these advantages provide the drug-loaded bioactive scaffolds with new choices for the treatments of IUAs.

1. Introduction
Intrauterine adhesions (IUAs), known as Asherman syndrome, are characterized by damage to the endometrium due to curettage or endometritis (Dreisler & Kjer, 2019). IUAs cause endometrial functional repair disorder leading to endometrial fibrosis. Approximately 25–30% of infertile women suffer from IUAs, which represents the most common cause of uterine infertility (Hanstede et al., 2015). It is also associated with the following gynecological diseases: hypomenorrhea, amenorrhea, recurrent abdominal pain, and recurrent spontaneous abortion. The traditional treatments for IUAs mainly focus on hysteroscopic transcervical resection of adhesion (TCRA) combined with postoperative management, including prevention of adhesion reformation (by the placement of an intrauterine device, foley catheter balloon, biomaterials, or other methods), and estrogen therapy for stimulation of endometrial regeneration (Khan & Goldberg, 2018). However, the recurrence of IUAs is still prevalent after various treatments, in severe cases, the incidence of adhesion reformation was reported to be as high as 62.5% (Rein et al., 2011). In addition, there are some disadvantages in available IUA treatments, including high recurrence rate, low pregnancy rate, and increased risk of thrombosis and breast tumors due to the high therapeutic dose of estrogen (Brown & Hankinson, 2015). Thus, it is highly desired to develop alternative approaches that lead to endometrial functional repair.

Tissue regeneration is considered to be a promising way for the treatment of IUAs. Recently, natural tissue-derived biomaterials have been increasingly applied to prevent postoperative re-adhesion (Kou et al., 2020). The amnion membrane (AM), a kind of prospective biomaterials, could not only act as a mechanical barrier to separate the wounded surface but also secrete various growth factors to activate the regulation of endometrial cell proliferation, migration, differentiation to achieve the morphological and functional recovery of the uterus (Shakouri-Motlagh et al., 2017). In the clinic, both the fresh and lyophilized amnion membranes have been used as anti-IUAs therapy (Cai et al., 2017; Li et al., 2020). However, AM may induce an immune response when integral membranes are transplanted into the majority of human tissues. Decellularized AM can reduce potential immunogenicity as the extracellular components of tissues are well tolerated even when used as xenografts (Aamodt & Grainger, 2016). In addition, by eliminating cellular components, the extracellular matrix (ECM) is more exposed, which promotes tighter cell-ECM interactions and results in more efficient cell attachment as well as stimulating different cell behaviors (Portmann-Lanz et al., 2007; Shakouri-Motlagh et al., 2017). ECM-derived scaffolds have been applied to promote the regeneration of...
various tissues in both preclinical and clinical types of research (Nogami et al., 2016; McQuilling et al., 2019), but there are no reports about the treatments of IUA with human amnion extracellular matrix (HAECM).

In order to improve the intrauterine drug concentrations of estrogen and reduce the severe side effects caused by high oral dose, we designed a kind of intrauterine drug sustained-release system based on HAECM bioscaffolds. Poly lactic-co-glycolic acid (PLGA) is an attractive polymer material due to its high biocompatibility, biodegradability, and excellent safety. PLGA microspheres have been demonstrated as effective carriers for estrogen in the drug delivery system (Sun et al., 2008). Zhang et al. reported that the application of 17β-estradiol (E2) released from the uterus improves the therapeutic effect for IUA in a rat model (Zhang et al., 2017). Hence, as shown in Figure 1, intrauterine HAECM-derived scaffolds embedded E2-PLGA microsphere (E2-MS) is introduced to be an efficient way to promote endometrial regeneration.

This work presents the first attempt to prepare a drug-delivering system based on HAECM scaffolds. Physicochemical properties of the scaffolds such as main composition, gelation kinetics, rheology, morphology, and drug release in vitro were investigated. Their biological properties, such as cytotoxicity, cell proliferation on the scaffolds, were evaluated to examine whether the scaffold composite could support endometrial cell adhesion, and growth. At last, the gene expressions of EGF, IGF-1, and their respective receptors in endometrial cells were analyzed after exposure to treatment groups.

2. Materials and methods

2.1. Materials

PLGA Resomer® RG 502 H (L:G 50:50, viscosity 0.16–0.24 dl/l, 7000–17,000 Mw), PLGA Resomer® RG 503 H (L:G 50:50, viscosity 0.32–0.44 dl/l, 24,000–38,000 Mw), and 17β-estradiol (E2) were was purchased from Sigma-Aldrich. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and tritonX-100 lysis buffer were obtained from Gibco (BRL, Gaithersburg, US). All other solvents and reagents were of analytical grade and used without further purification.

2.2. Cell culture

Ishikawa cells were provided by the Women’s Hospital School of Medicine Zhejiang University (Hangzhou, China). Ishikawa cells were cultivated in MEM supplemented with 5% FBS (v/v), 2 mM glutamine, 100 IU/ml penicillin G sodium and 100 mg/ml streptomycin sulfate at 37°C with 5% CO2 in a humidified incubator.

2.3. Amniotic membrane (AM) and decellularization

Term placentas with attached fetal membranes were collected immediately after uncomplicated cesarean section from healthy women, being tested negative for HIV, Hepatitis B and syphilis. The study and the use of the AM were approved by the Ethics Committee of the Women’s Hospital School of Medicine Zhejiang University. AM samples were carefully pulled apart from the chorion under sterile conditions, and the chorion was discarded. The membrane was washed several times with PBS containing 50 mg/ml penicillin and 50 mg/ml streptomycin to remove blood and blood clots. The membrane was cut into several 10 cm×10 cm pieces and agitated in 0.1% TritonX-100 for 6 h in room temperature, followed by rinsing with sterile PBS for 15 min. Next, the tissue was incubated in 0.25% Trypsin-EDTA solution overnight for cell removal. In order to eliminate nucleic acids completely, the tissues were then incubated in 1.8 M sodium chloride (NaCl) for 12 h to disrupt cell membranes and nuclear components. Finally, it was washed thoroughly with PBS, lyophilized and stored at 4°C until use.

2.4. Histology of HAECM

To examine the extent of decellularization of the amniotic membrane, both fresh and decellularized samples had been
embedded in O.C.T compound after fixing in 4% paraformaldehyde, then sectioned at 10 μm thickness using a microtome. Hematoxylin and eosin (H&E) stains were applied for histological analysis.

### 2.5. Hydrogels formation and glycosaminoglycans (GAGs), collagen analysis

The lyophilized decellularized AM was ground into powder at low temperatures and digested by 1 mg/ml pepsin in 0.1 M HCl solution followed by agitation on a shaker at 250 RPM for 72 h at room temperature. The digestion was stopped by pH adjustment to 7.2-7.4 using 0.1 M NaOH. The polymerization of neutralized HAECM hydrogel was initiated by incubation at 37 °C for a certain time.

The concentration of sulfated glycosaminoglycans (GAGs) in native AM and the neutralized HAECM hydrogel (5 mg/ml) were measured by the sulfated GAG assay kit (Biocolor, UK). The concentration of acid-pepsin soluble collagens (Types I to V) was determined by soluble collagen assay (Biocolor, UK). Three samples were picked for each assay.

### 2.6. HAECM hydrogel rheology and turbidimetric gelation kinetics

Gelation kinetics were determined by measuring the change in turbidity of various fibrin solutions. For each group, 150 μl/well of HAECM gel was added in a 96-well plate. The turbidity of hydrogels was measured by spectrophotometry with a microplate reader (Thermo MK3, US) at 550 nm every two mins for 60 mins at 37 °C.

The rheological characteristics of HAECM hydrogels were determined with a rotational rheometer (RS6000, HAAKE, Germany) operating with a 50 mm parallel plate geometry. The temperature was set to 37 °C, and the HAECM hydrogels with different concentrations were prepared and loaded into the rheometer. To obtain the dynamic viscosity, storage and loss modulus of the hydrogels, a dynamic time sweep test with a frequency of 1 rad/s and a strain of 1% was applied for 40 min.

### 2.7. Preparation of 17β-estradiol-loaded PLGA microspheres (E2-MS)

E2-MS were prepared by O/W emulsion-solvent extraction/evaporation method. We applied two PLGA materials: PLGA Resomer® RG 502 H (L:G 50:50, viscosity 0.16–0.24 dl/g, 7000–17,000 Mw), PLGA Resomer® RG 503 H (L:G 50:50, viscosity 0.32–0.44 dl/g, 24,000–38,000 Mw). Due to the lower solubility of estradiol in dichloromethane, ethyl acetate was selected as the organic phase. Briefly, 400 mg of PLGA and 40 mg of E2 were dissolved in 4 ml ethyl acetate. The organic phase was added dropwise to 40 ml of the inner aqueous phase containing 1.5% PVA. The entire mixture was emulsified by homogenization at 10,000 rpm for 2 min. The resulting emulsion was then added to 600 ml of distilled water and stirred at 250 rpm for 24 h at room temperature. The collected microspheres were washed three times in water and then lyophilized for 48 h (Labconco, FreeZone, Kansas City, MO) and stored –20 °C before further analysis.

### 2.8. Drug loading efficiency and entrapment efficiency

The concentrations of E2 in PLGA microspheres were measured by the HPLC method on Agilent 1100 series system (Agilent, Santa Clara, CA), consisted of a pump and a UV-Vis detector set at 280 nm. The analytical column was a C18 column (4.6 mm × 250 mm, 5 μm) (Agilent). The HPLC mobile phases consisted of methanol and water (65:35, v/v) at a flow rate of 1.0 ml/min. The injection volume was 20 μl. The quantification of E2 was performed using a resulting standard curve with the transformation of peak areas into the concentrations.

About 10 mg of the freeze-dried microspheres were dissolved in 1 ml of dichloromethane. The obtained solution was then diluted to 10 ml using methanol and vortex-mixed for 5 min. 1 ml of the dispersion was centrifuged at 8000 rpm (TGL-16G centrifuge, China) for 10 min. The concentrations of E2 were determined by taking the supernatant for HPLC system analysis. The drug loading efficiency (LE) and encapsulation efficiency (EE) were calculated by the following formulae:

\[
LE\% = \left( \frac{\text{Drug amount in microspheres}}{\text{Total amount of PLGA microspheres}} \right) \times 100
\]

\[
EE\% = \left( \frac{\text{Drug amount in microspheres}}{\text{Total drug amount}} \right) \times 100
\]

### 2.9. Preparation of porous HAECM scaffolds and HAECM scaffolds integrated with E2-MS

After gelation at 37 °C, the HAECM hydrogels with two different concentrations (5 mg/ml and 8 mg/ml) were frozen slowly in an isopropanol bath at −20 °C for 12 h and lyophilized. Next, the scaffolds were rehydrated in PBS at 37 °C for 12 h and rinsed with deionized water. The scaffolds were then lyophilized again and stored −20 °C.

E2-MS was dispersed in the HAECM hydrogels with two different concentrations (5 mg/ml and 8 mg/ml) to form the final microsphere-HAECM composite hydrogels at 37 °C. The final weight ratio of the microspheres was controlled as 30% of the total complex mass. Finally, porous complex scaffolds were prepared following the lyophilization protocol mentioned above.

The mean porosity of the different scaffolds was calculated as the relation between the void volume and the initial volume before lyophilizing.

### 2.10. Morphologic analysis

The shape and surface morphology of E2-MS, HAECM scaffolds, and microspheres-HAECM scaffolds were observed by a scanning electron microscope (SU8220 FEI Quanta 650, Livonia, MI). The samples of scaffolds were coated by ion
sputter gold under vacuum. The surface and structure morphology were analyzed, and the pictures were taken.

2.11. Drug release in vitro

2.11.1. Drug release from E2-MS

In vitro drug release from E2-MS was performed using the dialysis membrane method. The dialysis bags (cutoff Mw 8000–14,000, Sigma) were soaked in deionized water for 12 h before use. About 20 mg E2-MS were placed in a dialysis bag containing 1.5 ml of PBS (pH 7.4) and immersed into a flask with 40 ml of PBS (pH 7.4), which was shaken at 60 rpm. At the settled time point, 2 ml dissolution medium was withdrawn and an equal volume of fresh medium was added to the flask to maintain a constant volume. Then the samples were centrifuged at 10,000 rpm for 10 min. The amounts of E2 in the supernatant were analyzed by the HPLC system.

2.11.2. Drug release from E2-MS-HAECM scaffolds

In vitro drug release from lyophilized scaffolds was measured by ultrafiltration. 200 mg scaffolds (with two different concentrations: 5 mg/ml and 8 mg/ml) loaded with 30% E2-MS was placed into an ultrafiltration centrifuge tube (cutoff Mw 10,000, Millipore), and 10 ml PBS (pH 7.4) was added. The tube was shaken at 60 rpm at room temperature. At specific time points, the entire medium was removed and replaced by 10 ml fresh PBS. The samples were centrifuged at 10,000 rpm for 10 min. The amounts of E2 in the supernatant were analyzed by the HPLC system.

2.12. Ishikawa cells growth with E2-MS, free HAECM scaffolds, and E2-MS HAECM scaffolds

In order to evaluate the response of Ishikawa cells to different E2 concentrations, 10^4 cells were seeded on 96-well plates for 24 h and treated with E2 with different concentrations (0, 10, 100, 1000, and 10,000 nM) in triplicates. The proliferation of cells was evaluated by MTT reduction method after incubation for 24, 48, and 72 h. In brief, the cells were stained with MTT for 4 h and then dissolved in DMSO. Optical density (OD) was read with a microplate reader (Thermo MK3, Waltham, MA) at 570 nm. Cell proliferation was expressed as the ratio between the amount of formazan determined for cells treated with E2 of different concentrations and for nontreated cells.

For determining the effect of E2-MS, free HAECM scaffolds, and microspheres-HAECM complex scaffolds on Ishikawa cells, appropriate doses of E2-MS or scaffolds were added to each well on 6-well plates. After incubation for 24, 48, and 72 h, the cells were stained with MTT for 4 h and then dissolved in DMSO. A 100 µl solution was extracted from each well and transferred to a 96-well plate. The cell viability was assessed using the MTT assay as mentioned above.

Table 1. Primer sequences for quantitative real-time PCR

| Target gene | Primer Sequence |
|-------------|-----------------|
| GAPDH       | 5’-CTC ATG ACC ACA GTC CAT GC-3’ |
|             | 5’-TTG GCT TGA AAG GCA GA-3’ |
| EGF         | 5’-TGG GCT AAG AGG CAG TAA-3’ |
|             | 5’-TCA GCA GTG TCC AGA AAC-3’ |
| EGFR        | 5’-CTA GCA GTC TCC CAA CCC AA-3’ |
|             | 5’-AAG GCG AGC AAG CAG GGG-3’ |
| IGF-1       | 5’-CCA CCG TCA TGA CAG CAA GA-3’ |
|             | 5’-AGT ATC CCG AGA CAC TCT CC-3’ |

2.13. RNA isolation and quantitative real-time reverse transcription PCR (qRT-PCR) analysis

After incubation with different preparations for 72 h in 6-well plates, total mRNA from Ishikawa cells was extracted using the Trizol reagent. RNA was reversed to cDNA using a PrimeScript Reverse Transcription (RT) reagent kit (Takara) following the instructions. Specific primers used for amplification were synthesized by Generay (Shanghai, China; Table 1). Based on SYBR Premix Ex Taq™ kit (Takara, Japan), qRT-PCR reaction was performed with an ABI 7500 Thermocycler (Applied Biosystems, USA). For each sample, an average cycle threshold (Ct) value was calculated from triplicate wells, and GAPDH was used as the control of the input RNA level. The relative gene expression was calculated using 2^−ΔΔCt method.

2.14. Statistical analysis

Data are expressed as mean ± SD, and the statistical comparisons of means were performed by standard analysis of Graphpad prism 7.0. A p-value <.05 was considered statistically significant in all cases.

3. Result

3.1. Histology of amniotic membrane (AM) and decellularized AM

HE stains reveal that the AM is consists of three major layers: a single layer of columnar epithelial cells, attached to an underlying dense basement membrane, an acellular compact collagen-rich layer underneath, and finally a layer of dispersed fibroblasts (Figure 2(A)). The lack of staining for these cellular components further supported our successful decellularization results (Figure 2(B)).

3.2. Glycosaminoglycans (GAGs) and collagen analysis

Our research measured the content of GAGs between native AM and HAECM hydrogel. The native AM contained 3.09 ± 0.885 µg sulfated GAGs per mg tissue, while HAECM containing 6.72 ± 0.356 µg GAGs per mg hydrogel (Figure 2(C)). The concentration of GAGs in HAECM hydrogel...
was significantly higher than that of native AM ($p < .05$). The soluble collagen content in HAECM hydrogel with a concentration of 5 mg/ml was $0.497 \pm 0.05$ mg per mg hydrogel, while the native AM contained $0.273 \pm 0.057$ mg soluble collagen per mg tissue (Figure 2(D)), and there were significant differences among the different concentration of hydrogel ($p < .05$).

3.3. Gelation kinetics and rheological properties

HAECM hydrogels achieved 95% of its rigidity within 32 min after incubation initiation at 37°C (Figure 3(C)). The increase in the concentration of hydrogels (8 mg/ml versus 5 mg/ml) played a role in physical gel density but had no effect on gelation time.

As shown in Figure 3(D), both the storage modulus ($G'$) and the loss modulus ($G''$) changed over time and were characterized by a sigmoidal shape when the temperature of the samples was set to 37°C. $G'$ and $G''$ reached a steady-state after approximately 30–35 min, suggesting that gelation has been completed. Solid like behavior was confirmed because the $G'$ was about 5 times greater than the $G''$ after gelation. HAECM hydrogels showed an increase in the rate of gelation with increasing concentration. Indeed, the maximum $G'$ of the 8 mg/ml hydrogel was significantly higher than that of the 5 mg/ml hydrogel ($p < .05$) after gelation was completed (Figure 3(E)). As shown in Figure 3(F), the dynamic viscosity of each hydrogel was determined after inducing gelation, of which the change tendency was consistent with the result of $G'$ and $G''$ study.

3.4. Characterization of HAECM scaffolds and scaffolds integrated with E2-MS

The decellularized AM was digested into liquid form with pepsin, as shown in Figure 3(A), the HAECM hydrogel was a sol at room temperature, while crosslinked at 37°C (Figure 3(B)). The crosslinked hydrogels were then frozen under certain conditions and lyophilized, achieving solid, stable, and highly porous scaffolds that preserve their size and morphology after rehydration. Scanning electron microscopy (SEM) of HAECM scaffolds (Figure 4(C,D)) revealed their interconnected porous structure and changes in porosity with alteration of ECM concentrations (5 mg/ml versus 8 mg/ml). The pore size ranged 100–300 µm, it showed that ECM concentration also affected pore size, a higher concentration of the ECM components resulted in smaller pores.

Figure 4(E,F) showed that the E2-MS dispersed in HAECM scaffolds uniformly, interconnecting with macroporous spongy structures. The structure of E2-MS would achieve the release of E2 by diffusing through these fiber network structures. The incorporation of E2-MS had no effect on the porous structure of scaffolds, which could also be confirmed by the porosity study (Table 2).
3.5. Characteristics of E2-loaded PLGA microspheres (E2-MS)

3.5.1. Morphology and particle size
The surface morphology of E2-MS (502H) and E2-MS (503H) was examined visually by SEM. Photomicrographs of two PLGA microspheres loaded with E2 were shown in Figure 4(A,B). It was observed that the prepared drug-loaded microspheres were well sphere-shaped, homogeneous, and no crystalline of drugs or fragments of polymer exposed. The particles of PLGA microspheres were mainly 50–70 μm in diameter.

3.5.2. Drug loading efficiency and encapsulation efficiency
As shown in Table 3, the loading percentage of E2 determined in E2-MS (502H) and E2-MS (503H) was estimated to be 8.18 ± 0.17% and 7.73 ± 0.14%, respectively. The encapsulation percentage of E2-MS (502H) and E2-MS (503H) was estimated to be 89.9 ± 6.61% and 85.1 ± 7.83%, respectively.

3.6. In vitro drug release
In vitro drug release feature was important for characterizing the sustained released drug delivery system. As displayed in Figure 5, there was a certain burst drug release of E2-MS (502H) (about 30.33%) and E2-MS (503H) (23.67%) in 24 h. About 94.7% and 86.0% of E2 was released from E2-MS (502H) and E2-MS (503H) at the end of detection time. Figure 5 further confirmed the potential sustained release feature of the prepared scaffolds, the burst release rate was reduced, and the release rate in every stage was slower than E2-MS. Furthermore, the sustained-release lasted for about 21 days (94.3%) in E2-MS-HAECM scaffolds (5 mg/ml) group.
3.7. The proliferation of endometrial cell on HAECM scaffolds

To further investigate the ability of the HAECM scaffolds on supporting endometrial cells, the MTT assay was conducted.

After incubation with different concentrations of E₂ solution, the cell proliferation rate increased significantly at the

Table 2. Porosity of HAECM scaffolds with and without E₂-MS (n = 4).

|          | Porosity (%) | Entrapment efficiency (%) |
|----------|--------------|---------------------------|
| HAECM (8 mg/ml) | 78.90 ± 5.61  | 78.90 ± 5.61               |
| HAECM (8 mg/ml) + 30% E₂-MS | 75.12 ± 6.83  | 89.90 ± 6.61               |
| HAECM (5 mg/ml) | 90.38 ± 4.87  | 85.1 ± 7.83                |
| HAECM (5 mg/ml) + 30% E₂-MS | 88.15 ± 6.48  | 85.1 ± 7.83                |

Table 3. Drug loading efficiency (LE) and encapsulation efficiency (EE) (n = 4).

| Polymer | Drug loaded percent (%) | Entrapment efficiency (%) |
|---------|-------------------------|---------------------------|
| PLGA (502H) | 8.18 ± 0.17             | 89.90 ± 6.61              |
| PLGA (503H) | 7.73 ± 0.14             | 85.1 ± 7.83               |

Figure 4. Scanning electron microscopy photograph. (A) E₂-MS (502H). (B) E₂-MS (503H). (C) HAECM scaffold (5 mg/ml). (D) HAECM scaffold (8 mg/ml). (E) E₂-MS-HAECM scaffold with high magnification. (F) E₂-MS-HAECM scaffold with low magnification.

Figure 5. In vitro release profile of E₂ from PLGA microspheres and microsphere-HAECM scaffolds as a function time in PBS (pH 7.4) at 37 ± 0.5 °C. Data are presented as mean ± standard deviation; n = 3.
concentrations of 100 nM in all set incubation time (p < .05) (Figure 6(A)). According to the guidance of this result, 100 nM E2 was selected for subsequent experiments. As shown in Figure 6(B), compared to the control group, the significant proliferation of Ishikawa cells was noticed after treatment with E2-MS-HAECM scaffolds for 24, 48, and 72 h (p < .05). The proliferation rate in E2-MS-HAECM scaffolds group for 72 h was significantly higher than that in the other two groups (p < .05). When no E2-MS were added, the significant increase of proliferation rate in free HAECM scaffolds was observed compared to the control group in 72 h, indicating that the scaffolds offer a pleasant biocompatible environment for endometrial cell growth.

3.8. Effects of HAECM scaffolds on gene expression of cytokines and cytokine receptors

After Ishikawa cells were incubated with different preparations for 72 h, the gene expressions of EGF, IGF-1, as well as their respective receptors (EGFR and IGF-1R) were analyzed. As shown in Figure 7(A,B), the mRNA levels of the cytokines EGF and IGF-1 were all increased in three exposed groups compared to the control group. The significant increase of both cytokines was observed in E2-MS-HAECM scaffolds group and HAECM scaffolds group (p < .05). The changes of EGFR and IGF-1R expression (Figure 7(C,D)) were consistent with the results of mRNA levels change in EGF and IGF-1.

4. Discussion

Bioactive scaffolds composed of extracellular matrix (ECM) are widely used in the field of medical science, such as tissue engineering and stem cell therapy. ECM scaffolds are prepared by decellularization of natural tissues and the ECM provides different soluble factors, including growth factors and cytokines that facilitate the restoration of regular structure and functional tissue (Dziki & Badylak, 2018; Nie & Wang, 2018).

Our study of decellularized amnion scaffolds integrated with the PLGA microsphere for endometrial cell growth is
part of our laboratory’s research project and committed to developing biomaterial implants for application in IUAs. Because fertility issues are primary symptoms caused by severe IUAs, in consideration of female producibility and the safety of embryonic development, HAECM is considered as a potential multifunctional biomaterial for IUA treatment. When using the extracellular matrix for incubating cells or finally for implantation, it is essential to eliminate all antigens from tissues for preventing the immune response, while retaining the composition of the native ECM to the extent possible. How to achieve the balance between the preservation of essential bioactive substances and the elimination of possible. How to achieve the balance between the preservation of essential bioactive substances and the elimination of possible. How to achieve the balance between the preservation of essential bioactive substances and the elimination of possible. How to achieve the balance between the preservation of essential bioactive substances and the elimination of possible. How to achieve the balance between the preservation of essential bioactive substances and the elimination of possible. How to achieve the balance between the preservation of essential bioactive substances and the elimination of possible.

When using the extracellular matrix for incubating cells or finally for implantation, it is essential to eliminate all antigens from tissues for preventing the immune response, while retaining the composition of the native ECM to the extent possible. When using the extracellular matrix for incubating cells or finally for implantation, it is essential to eliminate all antigens from tissues for preventing the immune response, while retaining the composition of the native ECM to the extent possible. When using the extracellular matrix for incubating cells or finally for implantation, it is essential to eliminate all antigens from tissues for preventing the immune response, while retaining the composition of the native ECM to the extent possible. When using the extracellular matrix for incubating cells or finally for implantation, it is essential to eliminate all antigens from tissues for preventing the immune response, while retaining the composition of the native ECM to the extent possible.

Figure 2(A)). The results indicated that the sodium dodecyl sulfate (SDS), which is one of the anionic surfactants, leading to adverse effects on cell viability and tissue structure (Figure 2(A)). The results indicated that the sodium dodecyl sulfate (SDS), which is one of the anionic surfactants, leading to adverse effects on cell viability and tissue structure (Figure 2(A)). The results indicated that the sodium dodecyl sulfate (SDS), which is one of the anionic surfactants, leading to adverse effects on cell viability and tissue structure (Figure 2(A)).

The scaffold had a pore size of 100–300 μm with good pore connectivity and a porosity of 79–90%, which was suitable for tissue penetration and excellent extended drug release. As ECM concentration could affect pore size and porosity (Table 2), distinct pore structures and sizes can be achieved by adjusting matrix concentration or using different freezing regimes (Soffer-Tsur et al., 2017). In subsequent studies, we are going to optimize the morphology of scaffolds to make it a better drug microrepository.

Next, O/W emulsion-solvent evaporation was used to prepare E2-MS. The SEM images (Figure 4(A,B)) of the lyophlized loading E2-MS powder presented a round sphere with a poreless surface. The uniform-sized particles not only enhanced drug delivery but also decreased the adverse effects of the delivered drugs. It was shown that the size of E2-MS made by 502H was smaller than that of E2-MS made by 503H. Due to the different molecular weight of polymers, the particle size is slightly different, which had no significant effect on drug loading and entrapment efficiency (Table 3). To retain the original microstructure of the scaffolds, PLGA microspheres (<100 μm) were taken. The composite of the scaffold with 30% E2-MS did not alter the shape and particle size of the microspheres, while the scaffold morphology slightly changed after the introduction of E2-MS, inferring that the addition of microspheres did not damage the porous structure of the scaffold (Figure 4(E,F)). With the addition of E2-MS, the decrease in porosity was not significant (from 78.9 ± 5.61% to 75.12 ± 6.83% by 8 mg/ml; from 90.38 ± 4.87% to 88.15 ± 6.48% by 5 mg/ml, respectively). For practical applications, the microsphere content should be controlled below 50% (Tan et al., 2009), so that the resulting scaffolds have large enough pores (>200 μm) and porosity (>90%). These characteristics are advantageous for cell infiltration, proliferation, and migration (Zhou et al., 2005).

To investigate the effects of a different combination of microspheres or microsphere-scaffold system in drug delivery, the drug release rate of E2-MS-HAECM complex scaffold were compared with E2-MS. Results showed the drug release rate of E2-MS was faster than the complex scaffolds (Figure 5). PLGA microsphere is a kind of excellent sustained-release drug delivery system for hydrophobic drugs. The release mechanisms include PLGA degradation and drug diffusion (Kamaly et al., 2016). In our study, we have used two PLGA materials with different molecular weight, 502H was a low-Mw polymer, while 503H was a higher-Mw polymer. Low-Mw polymer carrier release drugs are faster by faster degradation, which is consistent with the drug release result in Figure 5. According to the completeness of drug release from microspheres, E2-MS by 502H is more suitable. Based on this result, we chose E2-MS by 502H to composite with HAECM scaffolds in the follow-up study. It should be noted that the two PLGA microspheres have the phenomenon of burst release, which is 23.67% and 30.33% in the first 24 h release, respectively. The burst release was caused by the E2 located at the surface of MS. When MS was embedded in the scaffolds, E2 released at a slower rate than from free E2-
MS. In the beginning, the burst release has been shown to be lowered due to the diffusional resistance caused by the scaffolds (Gu & Burgess, 2015), which maintain a neutral pH and are permeable to water and other small molecules. The scaffolds also provide a protective layer to maintain microsphere structure during drug release (Shen & Burgess, 2012). The E2 released from E2-MS-HAECM scaffold presented an initial burst release of 11.33 and 6.33% in the first 24 h, and then a relatively slower release up to 31.67 and 27.33% in the following 200 h. However, an increased E2 release occurred in the next 300 h, which can be attributed to the increased degradation of the HAECM scaffolds. Generally, a high degradation rate and swelling ratio of scaffold lead to a high diffusion rate of the MS from scaffolds, resulting in an increased drug release from the scaffold/MS (Sun et al., 2018). When the scaffold degraded completely, the drug release rate in the third stage mainly depends on the degradation of PLGA. In our study, the sustained-release of E2 lasted for about 21 days (94.3%) in E2-MS-HAECM scaffolds (5 mg/ml) group, which coincides with the secretion pattern of E2 during the female menstrual cycle. Compared with synthetic copolymer scaffolds (Rong et al., 2016; Zhang et al., 2018), the phenomenon of incomplete drug release has been improved. The increased concentration of scaffolds (8 mg/ml compared to 5 mg/ml) suggested reduced burst release and longer sustained release time due to their lower degradation rate of HAECM material in vitro. Therefore, the release profiles could be optimized by the properties of PLGA, the porosity, swelling, and degradation of the scaffolds based on the ECM concentrations and the ratio of MS/scaffolds. The controlled release of E2 from scaffolds was observed without a severe initial burst in 21 days, bringing the possibilities for improving the therapeutic effect for IUAs.

Furthermore, the ability of the HAECM scaffolds for supporting endometrial cells was evaluated. As shown in Figure 6(A), these cells require a medium supplemented with 100 nM E2; when given lower or higher E2 concentrations, the proliferation rate is lower, and the cell mortality rate is higher. The significant increase of proliferation rate in the free HAECM scaffolds showed excellent cytocompatibility of HAECM material, most cells exhibited normal and healthy morphology in the HAECM matrix. The results confirmed the manufactured scaffolds retain structural and functional properties required for cell growth in vitro. The highest proliferation rate was observed in E2-MS-HAECM scaffold in 72 h (Figure 6(B)), indicating the slow and stable release of E2 by the scaffolds is more conducive to the growth of endometrial cells than free E2. Therefore, the scaffolds could serve not only as a framework for physical supports but also as a comprehensive treatment device for regulating cell behaviors. Ding et al. developed a BMSCs loaded collagen scaffolds for the rat uterine regeneration after full-thickness injury (Ding et al., 2014). The BMSCs adhered to collagen scaffolds through interactions with the surface receptor, indicating a porous structure with suitable pore diameters, could promote the diffusion of oxygen and nutrients and the cell attachment.

To initially clarify the molecular mechanism of HAECM composite promoting endometrial growth, the following experiments focused on the gene expressions of EGF, IGF-1, and their respective receptors after exposure to treatment groups. Previous studies have reported that IGF-1 and EGF can promote the proliferation and migration of various types of cells, induce neovascularization to participate in tissue repair (Rijcken et al., 2014). As shown in Figure 7, when E2 solution was applied, the expression of EGF and IGF-1 did not change significantly, indicating that the effect of E2 on Ishikawa cells is independent of IGF-1 and EGF. However, the HAECM scaffold group and E2-MS-HAECM scaffold group increased mRNA levels of both cytokines significantly (p < .05). The results demonstrated EGF and IGF-1 are involved in endometrial proliferation, and HAECM partly promote the regeneration of endometrium through the EGF and IGF-1 family as an intermediary substance. Meanwhile, we found the expression of cytokines and their receptors peaked in E2-MS-HAECM scaffold group, suggesting the synergistic role of HAECM scaffold and E2 on endometrial regeneration, which was also supported by the results of cell proliferation (Figure 6).

Finally, the series of promising results in vitro need to be verified by animal experiments, additional experiments will be carried out to investigate therapeutic effects in IUA animal model, scaffold degradation rate in vivo, as well as the possible molecular mechanisms underlying the disease and healing.

5. Conclusions

Overall, this study describes an approach for the preparation of drug-delivering HAECM-derived scaffolds for endometrial cell growth. In the fabrication method, the addition of 30% E2-MS does not significantly modify the porous sponge structure of the scaffolds. Importantly, the composite improved the release properties of E2-MS by reducing the burst release. By adjusting the molecular weight of the PLGA polymer and the matrix concentration of the scaffolds, the goal of complete release in 21-day in vitro is achieved. Additionally, the cell proliferation experiments showed that slow and even release of E2 by the scaffolds is more conducive to the growth of endometrial cells than free E2. Therefore, more than creating a framework for simple mechanical supports, the advanced scaffolds provide higher functionality for the biologic guidance of endometrium regeneration.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

Funding from the Medicine and Health Science and Technology Plan in Zhejiang Province [2018KY429], the National Natural Science Foundation of China [81802587] and Natural Science Foundation of Zhejiang Province [LYY18H310001].
References

Aamodt JM, Grainger DW. (2016). Extracellular matrix-based biomaterial scaffolds and the host response. Biomaterials 86:68–82.

Bojarski KK, Karczyńska AS, Samsonov SA. (2020). The role of glycosaminoglycans in procathespin B maturation - molecular mechanism elucidated by a computational study. J Chem Inf Model 60:2247–56.

Brown SB, Hankinson SE. (2015). Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids 99:8–10.

Cai H, Qiao L, Song K, He Y. (2017). Oxidized, regenerated cellulose scaffolds and the host response. Biomaterials 86:68–82.

Ding L, Li X, Sun H, et al. (2014). Transplantation of bone marrow mesenchymal stem cells on collagen scaffolds for the functional regeneration of injured rat uterus. Biomaterials 35:4888–900.

Dreisler E, Kjer JJ. (2019). Asherman’s syndrome: current perspectives on diagnosis and management. Int J Womens Health 11:191–8.

Dziki JL, Badyak SF. (2018). Extracellular matrix for myocardialrepair. Adv Exp Med Biol 1098:151–63.

Gu B, Burgess DJ. (2015). Prediction of dexamethasone release from PLGA microspheres prepared with polymer blends using a design of experiment approach. Int J Pharm 495:393–403.

Hanstede MM, van der Meij E, Goedemans L, Emanuel MH. (2015). Results of centralized Asherman surgery. 2003-2013. Fertil Steril 104:1561–8.e1.

Hennink WE, van Nostrum CF. (2012). Novel crosslinking methods to control drug release. Chem Rev 116:2602–10.

Kamaly N, Yameen B, Wu J, Farokhzad OC. (2016). Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev 116:2602–63.

Khan Z, Goldberg JM. (2018). Hysteroscopic management of Asherman’s syndrome. J Minim Invasive Gynecol 25:218–29.

Kou L, Jiang X, Xiao S, et al. (2020). Therapeutic options and drug delivery strategies for the prevention of intrauterine adhesions. J Control Release 318:25–37.

Li C, Cai A, Sun C, et al. (2020). The study on the safety and efficacy of amniotic graft for preventing the recurrence of moderate to severe intrauterine adhesions. Genes Dis 7:266–71.

McQuilling JP, Sanders M, Poland L, et al. (2019). Dehydrated amnion/chorion improves Achilles tendon repair in a diabetic animal model. Wounds 31:19–25.

Neves MI, Araújo M, Moroni L, et al. (2020). Glycosaminoglycan-inspired biomaterials for the development of bioactive hydrogel networks. Molecules 25:978.

Nie X, Wang DA. (2018). Decellularized orthopaedic tissue-engineered grafts: biomaterial scaffolds synthesised by therapeutic cells. Biomater Sci 6:2798–811.

Nogami M, Kimura T, Seki S, et al. (2016). A human amnion-derived extracellular matrix-coated cell-free scaffold for cartilage repair: in vitro and in vivo studies. Tissue Eng Part A 22:680–8.

Portmann-Lanz CB, Ochssein-Kolble N, Marquardt K, et al. (2007). Manufacture of a cell-free amnion matrix scaffold that supports amnion cell outgrowth in vitro. Placenta 28:6–13.

Rein DT, Schmidt T, Hess AP, et al. (2011). Hysteroscopic management of residual trophoblastic tissue is superior to ultrasound-guided curettage. J Minim Invasive Gynecol 18:774–8.

Rijken E, Sachs L, Fuchs T, et al. (2014). Growth factors and gastrointestinal anastomotic healing. J Surg Res 187:202–10.

Rong ZJ, Yang LJ, Cai BT, et al. (2016). Porous nano-hydroxyapatite/collagen scaffold containing drug-loaded ADM-PLGA microspheres for bone cancer treatment. J Mater Sci Mater Med 27:89.

Shakouri-Motlagh A, Khanabdali R, Heath DE, Kalionis B. (2017). The application of decellularized human term fetal membranes in tissue engineering and regenerative medicine (TERM). Placenta 59:124–30.

Shen J, Burgess DJ. (2012). Accelerated in vitro release testing of implantable PLGA microsphere/PVA hydrogel composite coatings. Int J Pharm 422:341–8.

Soffer-Tsur N, Peer D, Dvir T. (2017). ECM-based macroporous sponges release essential factors to support the growth of hematopoietic cells. J Control Release 257:84–90.

Sun X, Wang J, Wang Y, Zhang Q. (2018). Collagen-based porous scaffolds containing PLGA microspheres for controlled kartogenin release in cartilage tissue engineering. Artif Cells Nanomed Biotechnol 46:1957–66.

Sun Y, Wang J, Zhang X, et al. (2008). Synchronous release of two hormonal contraceptives for about one month from the PLGA microspheres: in vitro and in vivo studies. J Control Release 129:192–9.

Tan H, Wu J, Lao G, Cao G. (2009). Gelatin/chitosan/hyaluronaln scaffold integrated with PLGA microspheres for cartilage tissue engineering. Acta Biomater 5:328–37.

Walimbe T, Panitch A. (2019). Proteoglycans in biomedicine: resurgence of an underexploited class of ECM molecules. Front Pharmacol 10:882.

Wolf MT, Daly KA, Brennan-Pierce EP, et al. (2012). A hydrogel derived from decellularized dermal extracellular matrix. Biomaterials 33:7028–38.

Zhang Q, Qin M, Zhou X, et al. (2018). Porous nanofibrous scaffold incorporated with S1P loaded mesoporous silica nanoparticles and BMP-2 encapsulated PLGA microspheres for enhancing angiogenesis and osteogenesis. J Mater Chem B 6:6731–43.

Zhang SS, Xia WT, Xu J, et al. (2017). Three-dimensional micelles of heparin-poloxamer improve the therapeutic effect of 17β-estradiol on endometrial regeneration for intrauterine adhesions in a rat model. J Nanomedicine 12:5643–57.

Zhou Q, Gong Y, Gao C. (2005). Microstructure and mechanical properties of poly(L-lactide) scaffolds fabricated by gelatin particle leaching method. J Appl Polym Sci 98:1373–9.